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Abstract: 
Bullatacin, a potential antitumor substance isolated from plants of the Annonaceae, and analogs of bullatacin, 
known collectively as acetogenins, have been reported previously to show potent activity in the inhibition of 
growth of murine tumors and human tumor xenografts grown in athymic mice as well as an ability to inhibit 
mitochondrial electron transport. In this report, we show activity of bullatacin in inhibition of NADH oxidase 
activity of plasma membrane vesicles isolated from HeLa cells and HL-60 cells but not with plasma membrane 
vesicles isolated from rat livers which, unlike the inhibition of mitochondrial activity, correlated with the ability 
of the acetogenins to kill tumor cells. Additionally, bullatacin is active against HL-60 cells that are resistant to 
adriamycin which may suggest utility for bullatacin in management of drug-resistant cells and cell lines. 
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Article: 
Various members of the plant family Annonaceae have yielded a group of bioactive secondary metabolites 
known collectively as the annonaceous acetogenins. These compounds are variously cytotoxic, pesticidal, 
antimalarial, antiparasitic, antimicrobial, and antineoplastic (1-3). A characteristic of these compounds, which 
helps to explain their cytotoxicity, is activity in the inhibition of mitochondrial electron transport (4, 5). 
However, a more selective activity also was sought that might help to explain the ability of certain members of 
the series to kill selectively transformed (cancer) cells under conditions where normal cells would be unharmed. 
 
Bullatacin is one of the most potent of the annonaceous acetogenins (4). This report concerns the response to 
bullatacin of a growth factor- and hormone-stimulated NADH oxidase activity of rat liver plasma membranes 
(6, 7). Several correlative studies have produced evidence for the involvement of this growth factor-responsive 
NADH oxidase in the control of cell proliferation (8). The activity in transformed cells and tissues was 
distinguished from that of liver in that the growth factor- and hormone-responsiveness was lost in plasma 
membranes of transformed liver tissues. These studies were with hyperplastic nodules of liver induced by the 
liver carcinogen, 2-acetylaminofluorene (9) and transplanted rat hepatomas (10). 
 
The NADH oxidase activity of liver plasma membranes is unique among oxidoreductase activities not only in 
its response to growth factors and hormones but, also, in its response to inhibitors and activators other than 
growth factors and hormones (8, 11, 12). In order to characterize further this unusual NADH oxidase activity, 
we extended our studies to include responses to bullatacin. 
 
The NADH oxidase activity of rat liver plasma membrane was largely unaffected by bullatacin, whereas the 
NADH oxidase activity of HeLa (human cervical carcinoma origin) and HL-60 (human promyelocytic leukemia 
origin) plasma membranes was strongly inhibited. The results indicate a fundamental difference in response to 
bullatacin between the NADH oxidase activity of liver and that of HeLa cells that may correlate with the 
previously reported potent inhibition of growth of transformed cells (1-3). 
 
Materials and Methods  
Growth of cells. HeLa (ATCC CCL2) cells were grown in 150 cm
2
 flasks in Minimal Essential Medium 
(Gibco), pH 7.4, at 37°C with 10% bovine calf serum (heat-inactivated), plus 50 mg/1 gentamycin sulfate 
(Sigma). Cells were trypsinized with Sigma IX trypsin for 1 to 2 min and harvested by scraping and taken up in 
140 mM NaC1, 5 mM KC1, 0.7 mM Na2HPO4 and 25 mM Tris, pH 7.4, to a final cell concentration of 0.1 g 
wet weight (gww) per ml. 
 
HL-60 cells were grown in RPM1-1640 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 
100 µg/ml streptomycin and 2.5 µg/ml amphotericin B. Cells were concentrated from stock cultures by 
centrifugation at 1000 x g and washed twice with serum-free RPM1-1640 medium and resuspended for assay in 
100 mM Tris-HC1, pH 7.4. 
 
Cells were from the American Type Culture Collection (Rockville, MD). The adriamycin-resistant cell lines 
were provided courtesy of Dr. Page Faulk, Methodist Hospital, Indianapolis, IN. All chemicals were from 
Sigma unless otherwise specified. Diferric transferrin was human holo (iron saturated) from Boehringer-
Mannheim (Lot #Fe2TF BLA 108). The epidermal growth factor was from mouse, culture grade, from Upstate 
Biotechnology Inc. (Lake Placid, NY). 
 
Purification of plasma membranes from rat liver. The 5000 x g pellet from the preparation of Golgi 
apparatus (13) was the starting material. The fluffy layer which contains the Golgi apparatus fraction was 
mixed, withdrawn and excluded from the plasma membrane preparations. Cold 1 mM NaHCO3 (5 ml) was 
added to each tube and the friable yellow-brown upper part of the pellet was resuspended with a pen-brush, 
leaving the reddish tightly packed bottom part of the pellet undisturbed. The resuspended material was 
homogenized in aliquots of 5 ml each in a 30 ml stainless steel (Duragrind) homogenizer 20 times by hand. The 
homogenates were combined, diluted with cold 1 mM NaHCO3 (1:1 dilution), and centrifuged at 6000 x g in a 
HB rotor for 15 min. The supernatant was discarded and the pellet was used for the two-phase separation (10). 
 
The two-phase system contained 6.4% (w/w) Dextran T-500 (Pharmacia), 6.4% (w/w) polyethylene glycol 3350 
(Fisher), and 5 mM potassium phosphate buffer (pH 7.2) (14). The homogenate (1 g) was added to the two-
phase system and the weight of the system was brought to 8 g with distilled water. The tubes were inverted 
vigorously for 40 times in the cold (4°C). The phases were separated by centrifugation at 750 rpm (150 x g) in a 
Sorvall HB 4 rotor for 5 min. The upper phases were withdrawn carefully with a Pasteur pipette, divided in half 
and transferred into 40 ml plastic centrifuge tubes. The tube contents were diluted with cold 1 mM NaHCO3 and 
collected by centrifugation at 10,000 x g in a HB rotor for 30 min. Plasma membrane pellets were resuspended 
in 50 mM Tris-Mes buffer (pH 7.2) and stored at -70°C. Proteins were determined using the bicinchoninic acid 
(BCA) assay (15) with bovine serum albumin as standard. Yields were approximately 3-5 mg plasma membrane 
protein per 10 g liver (16). 
 
The plasma membrane preparations from rat liver have been characterized extensively based on both 
morphological and enzymatic criteria (13, 15). From morphometric analysis using electron microscopy, the 
preparations contain 90 ± 4 percent plasma membrane. Contaminants include mitochondria (4%) and 
endoplasmic reticulum (3%). Based on analyses of marker enzymes, the contamination by endoplasmic 
reticulum was estimated to be 3%, that of mitochondria 15% and that of Golgi apparatus 1%. The recovery of 
plasma membranes was estimated to average 18% based on recovery of enzyme markers. 
 
Purification of plasma membranes from cultured cells. Cultured cells were collected by centrifugation for 6 to 
15 min at 1,000 to 3,000 rpm. The cell pellets were resuspended in 0.2 mM EDTA in 1 mM NaHCO3 in an 
approximate ratio of 1 ml per 10
8
 cells and incubated on ice for 10 to 30 min to swell the cells. Homogenization 
was with a Polytron Homogenizer for 30 to 40 sec at 10,500 rpm using a PT-PA 3012/23 or ST-probe in 7 to 8 
ml aliquots. To estimate breakage, the cells are monitored by light microscopy before and after homogenization. 
At least 90% cell breakage without breakage of nuclei was achieved routinely. 
 
The homogenates were centrifuged for 10 min at 1,000 rpm (175 g) to remove unbroken cells and nuclei 
and the supernatant was centrifuged a second time at 1.4 x 10
6
 g•min (e.g., 1 h at 23,500 g) to prepare a plasma 
membrane-enriched microsome fraction. The supernatant was discarded and the pellets were resuspended in 0.2 
M potassium phosphate buffer in a ratio of approximately 1 ml per pellet from 5 x 10
8
 cells. The resuspended 
membranes were then loaded onto the two-phase system constituted on a weight basis as described above for rat 
liver. The upper phase, enriched in plasma membranes, was diluted 5-fold with 1 mM sodium bicarbonate and 
the membranes are collected by centrifugation. The purity of the plasma membrane was determined to be > 90% 
by electron microscope morphometry. The yield was 20 mg plasma membrane protein from 10
10
 cells. 
 
Spectrophotometric assay of NADH oxidase. NADH oxidase activity was determined as the disappearance of 
NADH measured at 340 nm in a reaction mixture containing 25 mM Tris-Mes buffer (pH 7.2), 1 mM KCN to 
inhibit low levels of mitochondrial oxidase activity, and 150 µg NADH at 37°C with stirring. Activity was 
measured using a Hitachi U3210 spectrophotometer with continuous recording over two intervals of 5 min each. 
A millimolar extinction coefficient of 6.22 was used to determine specific activity. 
 
Results  
NADH oxidation by HeLa plasma membranes was reduced markedly by increasing concentrations of 
bullatacin. Drugs were added as DMSO solutions (final DMSO concentrations 0.1%). The immediate response 
to bullatacin addition was a temporary (1 to 2 min) stimulation of the activity followed by steady-state 
inhibition. Values presented are of the steady-state inhibitions. 
 
The dose response of HeLa plasma membranes to bullatacin summarized in Figure 1 indicated an ED50 of 5 to 
10 nM with nearly complete inhibition of the activity by 1 µg. The dose response to bullatacin was log linear 
over the range of 1 nM to 100 nM. 
 
In contrast to results with HeLa cell plasma membranes, plasma membranes of rat liver were unaffected by 
bullatacin over the concentration range of 1 nM to 10 µg (Fig. 2). At the highest concentrations tested of 1 and 
10 µg there appeared to be a slight but insignificant stimulation of the NADH oxidase activity. 
 
NADH oxidase activity of HL-60 cells also was inhibited by bullatacin. Of interest, however, was the ability of 
bullatacin to inhibit the NADH oxidase activity of HL-60 cells resistant to adriamycin (Fig. 3). More bullatacin 
was required to inhibit the NADH oxidase activity of the NADH oxidase from the adriamycin-resistant HL-60 
cells than was required to inhibit the NADH oxidase of plasma membranes from HeLa. Yet, the NADH oxidase 
of the plasma membranes of the adriamycin-resistant HeLa cells was strongly inhibited by 1 MM bullatacin. 
 
Other annonaceous acetogenins also inhibited the NADH oxidase of HeLa plasma membranes (Table 1). 
Asimicin inhibited with an ED50 of 5 nM and annonacin A which was the least growth inhibitory of the three (4) 
also exerted the smallest effect on the NADH oxidase (ED50 of 1 µg). Bullatacinone inhibited with an ED50 of 
0.1 µg to 1 µg. Asimicin was without effect on NADH oxidation of liver plasma membranes and bullatacinone 
gave only slight stimulations or inhibitions. With annonacin, an inhibition of about 30% was observed at 1 µg. 
 
 
Discussion  
In previous studies, the antitumor activity of annonaceous acetogenins has been investigated in in vivo tumor 
studies with normal mice (1-3). Promising antitumor activity of bullatacin and bullatalicin has been exhibited in 
athymic mice, and the mode of action has been investigated using Sf-9 (insect) cells and rat liver and beef heart 
mitochondria (4). The abilities to inhibit respiration and mitochondrial electron transport were reported (4), and 
the investigations have been extended to include all of the acetogenin subclasses (5). Bullatacin inhibited 
mitochondrial electron transport even in mitochondria from rat liver with IC-50 values down to 10 nM. The 
present report describes a new parameter, that of an NADH oxidase activity of the plasma membrane, which is 
resistant to bullatacin in preparations from normal rat liver but susceptible in HeLa and HL- 60 plasma 
membranes. 
 
Also in previous studies, an NADH oxidase activity of the plasma membrane of rat liver (6-8), keratinocytes 
(11) and plant stems (17), that was stimulated by hormones and growth factors, has been identified. In cancer, 
the activity was constitutively activated and no longer hormone-responsive (9, 10). The NADH oxidase activity 
of rat liver plasma membranes required quinones for activity (13). In plants, stimulation or inhibition of the 
activity correlated closely with inhibition or stimulation of growth (18, 19). 
 
In the present work, the NADH oxidase activity of HeLa cells (human cervical carcinoma derivation) was 
inhibited by bullatacin. In contrast to the NADH oxidase of HeLa plasma membranes, the NADH oxidase of 
plasma membranes from rat liver was not inhibited. Similarly, the NADH oxidase of HL-60 (human 
promyelocytic leukemia) cells resistant to adriamycin was inhibited by bullatacin. 
 
Not only does bullatacin inhibit the NADH oxidase of plasma membrane vesicles from HeLa cells and not that 
of liver, but the substance exerts a response on growth (2) parallel to that observed with NADH oxidase activity. 
While comparable growth studies were not done with HeLa, bullatacin and other active acetogenins inhibit 
growth of susceptible cell lines in culture in the nanomolar range of drug concentrations (4). 
 
These findings suggest that the inhibition of the activity of the NADH oxidase of the plasma membranes may 
correlate more closely with the antitumor activity of bullatacin, and, thus, the other acetogenins, than does the 
inhibition of mitochondrial electron transport. Furthermore, this new site of action, with its added vulnerability 
in transformed vs normal cells, may help to explain the in vitro and in vivo selectivity of the acetogenins toward 
transformed cells. 
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